TP53 and neoplasm: Accordingly, “extra‐nucleolar” PDCD11 should be defined as a tumor marker indicating an unfavorable prognosis and a potential therapeutic target (Figures 1 and 6), which acts as a C‐MYC partner to drive the development of breast and colon malignancies with p53 mutation.